FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved a supplemental application for RETEVMO (selpercatinib) from Eli Lilly, expanding its labeled indications for RET fusion–positive cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma
• Non-small Cell Lung Cancer
• Papillary Thyroid Carcinoma

Drugs mentioned

• RETEVMO (selpercatinib)

Snippet

SUPPL AP for RETEVMO (SELPERCATINIB)